SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Adicet Bio reports positive safety, efficacy data from prula-cel lupus study

The company said prula-cel was well tolerated, with no CRS above grade 2 and no IEC-HS or ICANS. It plans pivotal lupus nephritis trial start-up activities in Q4 2026 and expects a further data update in mid-2027.

ACET.O

Sept 28 (Reuters) — ADICET Bio, Inc.: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis Adicet Bio, - Prula-cel Shown To Be Well Tolerated With No Crs Above Grade 2 And No Iec-hs Or Icans Adicet Bio, - Plans To Initiate Pivotal Lupus Nephritis Trial Start-up Activities In Q4 2026 Adicet Bio, - All Patients Discontinued Immunosuppressants Adicet Bio, - At 12 Months, 54% Achieved Doris Remission And 50% Achieved Complete Renal Response Adicet Bio, - Anticipated Clinical Data Update In Lupus Nephritis/systemic Lupus Erythematosus In Mid 2027 Source text:...

Further company coverage: ACET.O (Reuters.Briefs@thomsonreuters.com;;)

Related stories